Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Monthly Archives: August 2014

2014 – FDA Recalls DePuy Craniomaxillofacial Distraction System, Cites Fatal Risk

Posted in Devices, FDA Regulation, Recalls

Recently, a craniofacial distraction implant by DePuy Orthopaedics was recalled.  This device, called the Craniomaxillofacial (CMF) Distraction System, “is a modular family of internal distraction devices that are used to gradually lengthen the mandible body and ramus” and indicated as “a bone stabilizer and lengthening (and/or transport) device for correction of congenital deficiencies or posttraumatic… Continue Reading

2014 – Birth defects risk increased 250% with Depacon / Depakene / Depakote

Posted in Depacon / Depakene / Depakote

In recent years, dozens of studies have been published illustrating an increased risk for birth defects linked to antiepileptic drugs containing sodium valproate such as Depacon, Depakene, and Depakote.  While these drugs are effective in the mitigation of seizures, the risks posed to developing babies cannot go overlooked.  Here, I will summarize one such study… Continue Reading

SSRIs linked to “abnormal development” of fetus

Posted in SSRI Birth Defects

In 2012, C.M. Nijenhuis and a team from University of Groningen (Groningen, The Netherlands) published a study titled “Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: Literature review.” in British Journal of Clinical Pharmacology.  There, the link between gestational exposure to selective… Continue Reading

2009 – Preterm birth again linked to SSRI exposure before birth

Posted in SSRI Birth Defects

Recently, I found an article titled “Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy.” that originally appeared in the December 2009 edition of American Journal of Obstetrics and Gynecology.  Published by R. Calderon-Margalit and a team from The University of Washington School of Public… Continue Reading

Risk for birth defects 47% higher with prenatal exposure to Depacon, Depakene, or Depakote

Posted in Depacon / Depakene / Depakote

In January of last year, a team of researchers led by E. Campbell published an article in Epilepsia titled “Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero.”, marking yet another piece of professional research illustrating the risks of prenatal exposure to drugs containing sodium valproate such as Depacon, Depakene, and… Continue Reading

Study shows: Depacon lifts risk for autism 300%

Posted in Depacon / Depakene / Depakote

Today, I found another article by G. Veiby and a team from The University of Bergen in Bergen, Norway that demonstrates the danger posed to children exposed to valproate in utero.  Valproate (sodium valproate, other formations) is the active chemical in a number of antiepileptic drugs such as Depacon, Depakote, and Depakene.  The article I… Continue Reading

2011 – Birth defect risk “significantly higher” with Depacon, Depakene, or Depakote exposure before birth

Posted in Depacon / Depakene / Depakote

In July, 2011, Lancet Neurology published an article titled “Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.” that was written by a team from Stockholm led by T. Tomson.  This study is yet another example of peer-reviewed research demonstrating that serious risks are posed to… Continue Reading

SSRIs in pregnancy linked to 12-fold increased risk for preterm birth

Posted in SSRI Birth Defects

Today, I came across an article published in a 2011 edition of Journal of Midwifery and Women’s Health by G. Latendresse and a team of researchers from The University of Utah College of Nursing (Salt Lake City) titled “Maternal corticotropin-releasing hormone and the use of selective serotonin reuptake inhibitors independently predict the occurrence of preterm… Continue Reading

2011 – Low gestational age linked to SSRI exposure, not maternal depression

Posted in SSRI Birth Defects

Titled “Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment.”, an article by A.L. Salisbury and a team from the Warren Alpert Medical School of Brown University, appearing in the December, 2011 edition of Depression and Anxiety, further explores the link between selective serotonin reuptake inhibitor drugs… Continue Reading

Neurological function adversely affected by maternal SSRIs

Posted in SSRI Birth Defects

In May, 2013, N.K. de Vries published an article titled “Early neurological outcome of young infants exposed to selective serotonin reuptake inhibitors during pregnancy: results from the observational SMOK study.” in the medical journal PLoS One.  This Dutch research team explored poor neonatal outcomes linked to selective serotonin reuptake inhibitor drugs (SSRIs). de Vries et… Continue Reading

2011 – Heart development affected by maternal SSRI use

Posted in SSRI Birth Defects

Published in the July, 2011 edition of Pediatric Research, a study by D. Rurak and a team from The University of British Columbia (Vancouver) titled “Third trimester fetal heart rate and Doppler middle cerebral artery blood flow velocity characteristics during prenatal selective serotonin reuptake inhibitor exposure.” examined the relationship between selective serotonin reuptake inhibitor drugs… Continue Reading

Study shows SSRIs affect fetal neurodevelopment

Posted in SSRI Birth Defects

From The Netherlands, a team of medical researchers led by E.J. Mulder published a study titled “Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus.” in the September, 2011 edition of Neuropsychopharmacology examining the relationship between exposure to selective serotonin reuptake inhibitor drugs (SSRIs) and adverse birth outcomes. The team states “The aim… Continue Reading

Autism, poor neurodevelopment linked to SSRIs in pregnancy

Posted in SSRI Birth Defects

An article titled “SSRI antidepressants: altered psychomotor development following exposure in utero?” that appeared in the February, 2013 edition of Prescrire International examines additional risks of prenatal exposure to selective serotonin reuptake inhibitor drugs (SSRIs).  To be clear, a number of other studies have linked adverse birth outcomes linked to SSRI exposure in years passed…. Continue Reading

2013 – Researchers show that SSRIs (not maternal depression) cause poor neonatal outcomes

Posted in SSRI Birth Defects

Last summer, a team of researchers from University of British Columbia (Vancouver) led by G.E. Hanley published a study titled “Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect.” in Early Human Development.  This study examined the relationship between poor early childhood development and gestational exposure to selective serotonin… Continue Reading

Prozac, Pazil, Zoloft, Celexa linked to Persistent Pulmonary Hypertension of the Newborn (PPHN)

Posted in Celexa Birth Defects, Effexor Birth Defects, Paxil Birth Defects, Prozac Birth Defects, SSRI Birth Defects, Zoloft Birth Defects

Titled “Further findings linking SSRIs during pregnancy and persistent pulmonary hypertension of the newborn: clinical implications.”, this article appearing in the October, 2012 edition of CNS Drugs by M. Galbally et al., identifies persistent pulmonary hypertension of the newborn (PPHN) as a potential consequence of SSRI exposure before birth. Galbally et al. (2012) writes “Persistent… Continue Reading

2006 – Persistent Pulmonary Hypertension Linked to SSRIs in Pregnancy

Posted in SSRI Birth Defects

A team of researchers from Sydney, Australia (led by M.P. Austin) published an article in a December, 2006 edition of Psychological Medicine titled “To treat or not to treat: maternal depression, SSRI use in pregnancy and adverse neonatal effects.” that attempted to clarify negative consequences of prenatal exposure to SSRI drugs like Prozac, Paxil, and… Continue Reading

More research links poor development with SSRI exposure

Posted in SSRI Birth Defects

An article in Early Human Development (February, 2013) by M.V. Smith et al. titled “Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors.”, from The Yale School of Medicine delves further into the link between prenatal SSRI exposure and adverse birth outcomes.  Selective serotonin reuptake inhibitor drugs (SSRIs) are… Continue Reading

Huge birth defect increase with Depacon / Depakene / Depakote in pregnancy

Posted in Depacon / Depakene / Depakote

Today, I came across an article from the February, 2012 edition of The Australian and New Zealand Journal of Obstetrics and Gynecology published by F.J. Vajda and a team of researchers at University of Melbourne (Australia).  In their piece, titled “The prescribing of antiepileptic drugs for pregnant Australian women.” Vajda et al. explore further the… Continue Reading

JAMA: Autism risk 500% increased with Depakote, Depakene, and Depacon in utero

Posted in Depacon / Depakene / Depakote

In the April, 2013 edition of JAMA, an article titled “Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.” from a Danish team led by J. Christensen evaluated the risks of prenatal exposure to the antiepileptic Depacon.  Because Abbott Laboratories, the manufacturer of this drug, failed time and again to warn of… Continue Reading

Birth defects at significantly higher rate with Depacon, Depakene

Posted in Depacon / Depakene / Depakote

Titled “Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.”, an article by J. Morrow and a team from Belfast (UK) published in the February, 2006 edition of Journal of Neurology, Neurosurgery, and Psychiatry aimed to “assess the relative risk of major congenital malformation (MCM) from in… Continue Reading

2014 – Increased risk for birth defects seen with Depakote exposure

Posted in Depacon / Depakene / Depakote

In July, 2014, a team of Norwegian researchers led by K.O. Nakken published an article in Tidsskr Nor Laegeforen titled “Antiepileptic drugs and congenital malformations”, evaluating the consequences of prenatal exposure to epilepsy drugs containing sodium valproate, such as Depacon, Depakene, and Depakote (Abbott Laboratories, Inc.).  To-date, dozens of studies have demonstrated that a dramatically-increased… Continue Reading

2008 – Epilepsy drugs with valproate linked to higher risk of birth defects, low IQ

Posted in Depacon / Depakene / Depakote

From Stockholm, Sweden, a 2008 piece titled “Teratogenic effects of antiepileptic drugs.” and appearing in the medical journal, Seizure, by T. Tomson et al. yet again demonstrates the postnatal risks of prenatal exposure to epilepsy drugs containing sodium valproate such as Depakote, Depakene, and Depacon (Abbott Laboratories, Inc.). Here, it is stated that “The use… Continue Reading

Harvard: Depacon, Depakote, Depakene linked to poor birth outcomes

Posted in Depacon / Depakene / Depakote

In recent years, a number of studies have shown that prenatal exposure to sodium valproate (the active ingredient in epilepsy drugs Depacon, Depakene, and Depakote) is linked to increased risk for birth defects.  Here, I’ll summarize one such study, titled “Differential effects of antiepileptic drugs on neonatal outcomes.” by P.B. Pennell and a team from… Continue Reading

1992 – Japan finds Depakote, Depakene, Depacon associated with higher birth defect rate

Posted in Depacon / Depakene / Depakote

Titled “Malformation in infants of mothers with epilepsy receiving antiepileptic drugs.”, a piece of Japanese medical research by S. Kaneko et al. published in April, 1992 helps show just how long it has been known that prenatal exposure to epilepsy drugs containing valproate is linked to birth defects.  Depacon, Depakote, and Depakene are top examples… Continue Reading